medigraphic.com

2012, Número 3

<< Anterior

Rev Latinoam Psiquiatría 2012; 11 (3)


Manifestaciones psiquiátricas en la enfermedad de Parkinson: a propósito de un caso

Pezoa JRE

Idioma: Español
Referencias bibliográficas: 39
Paginas: 116-122
Archivo PDF: 248.42 Kb.


RESUMEN

Se describe el caso de una paciente internada en el servicio de Neuropsiquiatría del Instituto Nacional de Neurología y Neurocirugía (INNN) debido a una gama de manifestaciones psiquiátricas asociadas con enfermedad de Parkinson. El objetivo de esta presentación es describir el cuadro clínico de las manifestaciones neuropsiquiátricas de la enfermedad de Parkinson y revisar la bibliografía relacionada con este padecimiento.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783-1793.

  2. Rodríguez Violante M, Villar Velarde A, Valencia Ramos C, Cervantes Arriaga A. Características epidemiológicas de pacientes con enfermedad de Parkinson de un hospital de referencia en México. Arch Neurocien Mex 2011;16:64-68.

  3. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.

  4. O'Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira- Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson's disease: A clinicopathological study. Mov Disord 2008;23:101-106.

  5. Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Neurology 2008;255:255-64.

  6. Schneider F, Althaus A, Backes V, Dodel R. Psychiatric symptoms in Parkinson’s disease. Eur Arch Psychiatry Clin Neuroscience 2008;258:55-9.

  7. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Nonrecognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism & Related Disord 2002;8:193-7.

  8. Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197-211.

  9. Lang AE. A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord 2011;26:775- 783.

  10. Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurology 2009;8:464-474.

  11. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149:443-454.

  12. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128:1314-1322.

  13. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Experim Neurology 1991;50:743-755.

  14. Sano M, Stern Y, Williams J, Cote L, Rosenstein R, Mayeux R. Coexisting dementia and depression in Parkinson's disease. Arch Neurology 1989;46:1284-1286.

  15. Kostic VS, Agosta F, Petrovic I, et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology 2010;75:857-863.

  16. Schwarz J, Odin P, Buhmann C, et al. Depression in Parkinson’s disease. J Neurology 2011;258:336-338.

  17. Williams JR, Hirsch ES, Anderson K, et al. A comparison of nine scales to detect depression in Parkinson disease. Neurology 2012;78:998-1006.

  18. Veazey C, Aki SO, Cook KF, Lai EC, Kunik ME. Prevalence and treatment of depression in Parkinson's disease. Journal Neuropsychiatry Clin Neurosciences 2005;17:310-323.

  19. Kennedy R, Mittal D, O'Jile J. Electroconvulsive therapy in movement disorders: an update. Journal Neuropsychiatry Clin Neurosciences 2003;15:407-421.

  20. Alegret M, Junqué C, Valldeoriola F, Vendrell P, Martí MJ, Tolosa E. Obsessive-compulsive symptoms in Parkinson's disease. Journal Neurology Neurosurg Psychiatry 2001;70:394-396.

  21. Marsh L. Anxiety disorders in Parkinson’s disease. International Rev Psychiatry 2000;12:307-318.

  22. Vázquez A, Jiménez-Jiménez FJ, García-Ruiz P, García-Urra D. “Panic attacks” in Parkinson's disease. Acta Neurol Scand 1993;87:14-18.

  23. Müller N, Putz A, Kathmann N, Lehle R, Günther W, Straube A. Characteristics of obsessive–compulsive symptoms in Tourette's syndrome, obsessive–compulsive disorder, and Parkinson's disease. Psychiat Res 1997;70:105-114.

  24. Chen JJ. Anxiety, depression, and psychosis in Parkinson's disease: unmet needs and treatment challenges. Neurol Clin 2004;22:S63-90.

  25. Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990;147:217-220.

  26. Maia AF, Pinto AS, Barbosa ER, Menezes PR, Miguel EC. Obsessive-compulsive symptoms, obsessive-compulsive disorder, and related disorders in Parkinson's disease. Journal Neuropsychiatry Clin Neurosciences 2003;15:371-374.

  27. Bosboom J, Corona T, Wolters E. Psicosis en la enfermedad de Parkinson. Archiv Neurociencias 2004;9:25-33.

  28. Wolters EC. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology 1999;52:S10-3.

  29. Eng ML, Welty TE. Management of hallucinations and psychosis in Parkinson's disease. Am J Geriatr Pharmacother 2010;8:316-330.

  30. Noé-Sebastián E, Irimia P, Pomares-Arias EM, Martínez-Vila E, Luquin MR. Trastornos neuropsiquiátricos en la enfermedad de Parkinson. Rev Neurology 2001;32:676-681.

  31. Friedman JH. Parkinson’s disease psychosis 2010: A review article. Parkinsonism Related Disord 2010;16:553-560.

  32. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson’s disease. J Neurology Neurosurg Psychiatry 1998;64:533-535.

  33. Group TPS. Low-Dose Clozapine for the Treatment of Drug- Induced Psychosis in Parkinson's Disease. N Eng J Medicine 1999;340:757-763.

  34. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurology, Neurosurg Psychiatry 2004;75:689-695.

  35. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003;18:510-514.

  36. López del Val LJ, Santos-Lasaosa S. Quetiapina y ziprasidona en el tratamiento de los trastornos psicóticos de la enfermedad de Parkinson. Rev Neurology 2004;39:661-667.

  37. Ondo WG, Tintner R, Dat Voung K, Lai D, Ringholz G. Doubleblind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-963.

  38. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: A double-blind labeled study of 3 months' duration. Mov Disord 2007;22:313-318.

  39. Kurlan R, Cummings J, Raman R, Thal L, Alzheimer's Disease Cooperative Study G. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007;68:1356-1363.




2020     |     www.medigraphic.com